Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > REGULATORY
REGULATORY
- WT of DPJ Begins Discussion, Not Yet Known If It Covers Drug Pricing System
October 31, 2011
- Medical Benefits Rose 4.2% in FY2009, Breaking ¥30 Tril. for 1st Time
October 31, 2011
- Drug-induced Hepatitis Victims, Lawyers Petition Against Establishment of “Third Party Organization”
October 31, 2011
- MHLW Research Team Looks Into Compliance Systems, Gathering Advanced Case Studies
October 28, 2011
- CSIMC's Drug Price Committee Agrees to Review Foreign Price-Based Adjustments, Increase Downward Revising
October 28, 2011
- MHLW Varies Direction of Revision with Innovative Evaluation and Efficiency
October 28, 2011
- MHLW Calls for Package Insert Revisions for 6 Products Including Strattera
October 28, 2011
- US FDA Extends Action Date for SGLT-2 Inhibitor Dapagliflozin
October 28, 2011
- Mr Yoshimura of Astem to Be Named as Successor of Mr Matsutani: CSIMC Expert Member
October 28, 2011
- Drug-induced Hepatitis Victims Petition Against Creation of Korosho-Proposed “Third-Party Organization”
October 28, 2011
- Korosho Study Group Surveying Drug Makers’ Regulatory Compliance Systems
October 28, 2011
- Medical Benefits Rose 4.2% in FY2009, Breaking ¥30 Tril. for 1st Time
October 28, 2011
- MHLW Releases Safety Information, Calling for Proper Use of Champix
October 27, 2011
- Subcommittee to Recommend Use of Most-recent 3-Year Averages in Drug Cost Calculation
October 27, 2011
- Planning to Resume “Public-Private Dialog” by Year-End: EAD Director Kamata
October 27, 2011
- DPJ Lawmakers Opposed to TPP Criticize MHLW at Hearings
October 27, 2011
- DPJ Lawmakers Opposed to TPP Criticize Korosho at Hearings
October 26, 2011
- New Rules for Application of GCP Ordinance to Take Effect April 1, 2012
October 26, 2011
- Supreme Court Upholds Ban on Reimbursement in “Mixed Healthcare”
October 26, 2011
- US FDA Approves 1st Generic Versions of Zyprexa, Eli Lilly’s Top Mainstay Product
October 26, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…